



Erratum to clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma

Editorial Office

Translational Lung Cancer Research

Correspondence to: Editorial Office. Translational Lung Cancer Research. Email: editor@tlcr.org.

Submitted Jul 09, 2022, Accepted for publication Nov 01, 2022

doi: 10.21037/tlcr-2022-6

View this article at: <https://dx.doi.org/10.21037/tlcr-2022-6>

Erratum to: *Transl Lung Cancer Res* 2022;11:420-31

This article (1) titled “Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma” (doi: 10.21037/tlcr-22-190), unfortunately contains an error in the primary affiliation for Haimiao Xu and Guoping Cheng. The current affiliation 8 should be the primary affiliation for Haimiao Xu and Guoping Cheng. Therefore, a superscript “**” should be added to the 8th affiliation for explanation.

The corrected author info is as follows:

Xiaoling Xu^{1,2#}, Wenming Shen^{3#}, Ding Wang^{2,4#}, Na Li⁵, Zhiyu Huang^{1,2}, Jiamin Sheng^{1,2}, A. Justin Rucker⁶, Weimin Mao^{2,7}, Haimiao Xu^{2,8}, Guoping Cheng^{2,8}

¹Department of Thoracic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; ²Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China; ³Department of Cardiothoracic Surgery, Ningbo Yinzhou No. 2 Hospital, Ningbo, China; ⁴The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China; ⁵Shaoxing No. 2 Hospital Medical Community General Hospital, Shaoxing, China; ⁶Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA; ⁷Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; ⁸Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China*

Contributions: (I) Conception and design: G Cheng, H Xu, W Mao; (II) Administrative support: X Xu, W Shen; (III) Provision of study materials or patients: N Li, Z Huang; (IV) Collection and assembly of data: D Wang, X Xu; (V) Data analysis and interpretation: X Xu, J Sheng; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work and should be considered as co-first authors.

*The current affiliation 8 should be the primary affiliation for Haimiao Xu and Guoping Cheng.

Correspondence to: Guoping Cheng; Haimiao Xu; Weimin Mao. The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China. Email: chengguoping1218@163.com; xuhm@zjcc.org.cn; maowm1318@163.com.

The authors apologize for the oversight.

Click [here](#) to view the updated version of the article.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Xu X, Shen W, Wang D, et al. Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma. *Transl Lung Cancer Res* 2022;11:420-31.

Cite this article as: Editorial Office. Erratum to clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma. *Transl Lung Cancer Res* 2022;11(12):2608-2609. doi: 10.21037/tlcr-2022-6